Condition: ALK Gene Mutation · NSCLC Stage IV · ALK Sensitizing Mutation · Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
The scope of GALILEO project (Genomic ALteratIons and cLonal EvOlution in ALK+ NSCLC) is to explore the feasibility of genomic longitudinal evaluation for ALK+ NSCLC patients in Italian routine practice and provide a detailed overview of resistance mechanisms and clinical outcomes according to current standard treatments.
This description comes directly from the study's public registry record.
Emanuele Vita, MD · 3480510228 · dr.emanuele.vita@gmail.com
EMILIO Bria, Prof. · 0630156318 · emilio.bria@policlinicogemelli.it
Always discuss trial participation with your own doctor first.
| Fondazione Policlinico Gemelli IRCCS | Rome, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06234579